Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...
We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...
Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Corbus Pharmaceuticals (CRBP – Research Report). The associated price target remains the same with $80.00. Andres Y ...
Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) has received an average recommendation of “Buy” from ...
On Wednesday, B.Riley initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and a price target of $85.00. The firm's coverage is based on the potential of... NORWOOD, MA ...
Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback